secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001193125-24-001977
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics appoints Noriyuki Kasahara as Chief Scientific Officer effective Jan 2, 2024
--------------------------------------------------------------------------------

- Noriyuki Kasahara, M.D., Ph.D., appointed CSO effective January 2, 2024.
- Kasahara resigned from the Board and as Chair of the Science and Technology Committee on January 1, 2024.
- Resignation not due to any disagreement with the Company or Board.
- He transitions from Board member to executive officer role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312524001977/0001193125-24-001977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312524001977/d624050d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-001977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer